Pfizer Reports Decent Third-Quarter Results; Loss of Exclusivity on Blockbuster Drug Lipitor Concerning
Pfizer (PFE) reported strong third-quarter results Tuesday that showed decent top-line growth thanks to favorable foreign exchange and solid income expansion due to excellent cost controls, which offset product losses of exclusivity. We are maintaining our fair value estimate. Pfizer’s top line jumped 7%, which was driven almost entirely by favorable foreign exchange (international revenue growth was 15%; 4% operational with the balance forex). US revenues continue to decline and also fall as a percentage of total revenue (now 40%, was 44%). Operationally, Pfizer experienced the strongest growth in nutrition, animal health (due to the addition of legacy King products), and consumer healthcare. Revenue from its largest segment, Primary Care, was essentially flat, while sales from its second-largest segment, Specialty … Read more